Nanobiotix Provides First Quarter 2026 Operational and Financial Update
View original at finance.yahoo.comNanobiotix Provides First Quarter 2026 Operational and Financial Update Nanobiotix S.A…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Complete response rate of 57.1% (4/7 patients) observed in CONVERGE Part 1 cohort, reported at ESTRO 2026
60% confidenceWith standard of care (cCRT ± durvalumab), depth of response in Stage 3 Inoperable NSCLC is limited with very low rates of complete response below 5%
60% confidenceNanoprimer pre-treatment followed by LNP-DNA administration showed increased systemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING related inflammation compared to LNP-DNA alone in preclinical data
60% confidenceAbsence of progressive disease and deepening response over time in CONVERGE patients suggests potential for long-term durability of JNJ-1900 treatment
60% confidenceORR of 71.4% (5/7 patients) observed at earlier time point in same CONVERGE cohort and reported at ELCC 2026
60% confidenceEarly results suggest intratumoral/intranodal injection of JNJ-1900 is feasible and can be performed safely in patients with stage III unresectable NSCLC
60% confidenceOverall response rate of 85.7% (6/7 patients) observed in CONVERGE Part 1 cohort following full treatment regimen of cCRT, JNJ-1900, and durvalumab consolidation, reported at ESTRO 2026
60% confidenceCONVERGE treatment procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events
60% confidenceNanobiotix continues to advance with focus, discipline, and ambition to unlock the full potential of physics-based nanotherapeutics; Q1 2026 strengthened the foundation via JNJ-1900 advancement, Nanoprimer progress, and reinforced financial position
60% confidence